Chryseobacterium (Flavobacterium) spp.: Clinical Significance, Identification, Antimicrobial Susceptibility | CMAC

Chryseobacterium (Flavobacterium) spp.: Clinical Significance, Identification, Antimicrobial Susceptibility

Clinical Microbiology and Antimicrobial Chemotherapy. 2003; 5(3):243-250

Journal article


Along with known human pathogens, such as Pseudomonas aeruginosa, Acinetobacter spp., Burkholderia spp., group of non-fermentative Gram-negative rods includes gender Chryseo4 bacterium (former Flavobacterium). Chryseo-bacteria are ubiquitous microorganisms, which may contaminate hospital environment and be a source of infection for hospitalized patients. Of the Chryseobacterium species, C. meningo4 septicum is the most important human pathogen, which may cause infections (primarily nosocomial), especially in immunocompromised patients. The main clinically significant types of infection, caused by C. meningosepticum are neonatal meningitis and bacteremia, especially in premature infants in the intensive care units, and nosocomial pneumonia. The most common presentation of Chryseobacterium spp. infection in adults is pneumonia, which is usually associated with mechanical ventilation. Chryseobacterium spp. are usually resistant to most antimicrobials, used for treatment of infections, caused by Gram-negative microorganisms, – aminoglycosides, β-lactams, tetracyclines, chloramphenicol, but susceptible to such antimicrobials, as vancomycin, rifampicin, clindamycin, and in many cases to trimethoprim/sulfamethoxazole. Initial regimens for the treatment of clinically significant Chryseobacterium spp. infections include rifampicin in combination with vancomycin or trimethoprim/sulfamethoxazole, a fluoroquinolone.

0 Abstract
0 Crossref citations